34 results about "Cutaneous wound" patented technology

The present invention relates to a monolithic biomaterial. The monolithic biomaterial has a primary network of convective flow, microfluidic channels that are embedded in a substrate, where the substrate is diffusively permeable to aqueous solutes. The present invention also relates to a method of making the monolithic biomaterial, as well as methods of using the monolithic biomaterial to facilitate healing of a cutaneous wound of a mammalian subject and of regulating cells.

A method for restructuring a biological tissue comprising collagen fibrils selected from a venous tissue, a cardiac valvular tissue, a cutaneous or subcutaneous tissue, a tissue of a muscular tendon, a tissue of a muscular fascia or a tissue of a muscular aponeurosis, comprising the following operational steps: a) bringing into contact a biological tissue comprising collagen fibrils with a cross-linking chemical composition able to induce cross-linking of collagen fibrils consequent to activation through electromagnetic radiation; b) activating said cross linking chemical composition through exposure to an electromagnetic radiation; c) cross-linking the collagen fibrils of said biological tissue in order to obtain a restructured biological tissue. The method according to the invention can be applied to recover a venous continence and both a venous and a cardiac valve diameter. The method reduces the visibility of cutaneous wrinkles, reinforces or repairs tendons, muscular fascia and aponeurosis as well as to heals surgical or traumatic cutaneous wounds or cutaneous ulcers.

Disclosed is a method of promoting wound healing or wound closure. The method comprises administration of a miR-198 inhibitor and / or a follistatin-like-1 (FSTL1) polypeptide. Also disclosed are method of treating chronic cutaneous wounds, method of identifying a non-healing wound, use and a pharmaceutical composition comprising a miR-198 inhibitor and / or a follistatin-like-1 (FSTL1) polypeptide.

The invention relates to wound repair and healing, particularly to dermal or cutaneous wounds including but not limited to acute and chronic wounds, burns and ulcers.

The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and / or an inhibitor of the Nax / SCN7A pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound. The present invention also provides compositions, kits, devices, and methods for treating skin conditions (e.g., dermatitis, psoriasis, or other skin conditions) with such compositions and devices. Examples of such therapeutic agents include, but are not limited to, an inhibitor of a gene or protein selected from: ENac, COX-2, PGE2, PI3K, PKB, Nax Prss8, IL-1β, IL-8, SAPK, Erk gene, p38 gene, PAR2, S100A8, S100A9, S100A12.

The present invention provides compositions and methods that promote wound healing in a subject with a cutaneous injury. In particular, the present invention provides systemic and / or local administration of one or more compositions that cause ganglioside depletion (e.g., glucosylceramide synthase (GCS) inhibitors) for the treatment of cutaneous wounds.

The invention relates to a field of tissue repair and regeneration. More particularly, the invention relates to a composition for promoting cutaneous wound healing. In one embodiment, the composition is composed of one or more metazoan parasites or a mimic thereof sufficient to promote helminth-induced type-2 immune response. Preferably, the composition contains N. brasiliensis excretory / secretory antigen (NES) or an immune triggering portion thereof. The invention also relates to a method of accelerating wound healing in a subject in need of such treatment.

The object of the present invention is a composition in powder form comprising the following polysaccharides alginic acid or sodium alginate, - pectin, chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder. The process for preparing said powder by an atomization process and its use in the treatment of cutaneous wounds and in the sector of food preservation are additional objects of the invention. Moreover, additional objects of the invention are the composition in the form of solution or liquid suspension that represents the starting material to obtain said powder and the process for preparing said liquid composition.